|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"baselga j"
Showing items 11-14 of 14 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2017 |
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
|
Kim S.-B.;Maslyar D.J.;Dent R.;Im S.-A.;Espi? M.;Blau S.;Tan A.R.;Isakoff S.J.;Oliveira M.;Saura C.;Wongchenko M.J.;Kapp A.V.;Chan W.Y.;Singel S.M.;Baselga J.;Kim S.-B.;Lee K.S.;Im S.-A.;Espi? M.;Wang H.-C.;Blau S.;Dent R.;Tan A.;Sohn J.H.;De Laurentiis M.;Estevez L.G.;Chiun-Sheng Huang;Romieu G.;Velez M.;Villanueva R.;Conte P.F.;Dakhil S.;Debled M.;Martin A.G.;Hurvitz S.;Kim J.H.;Levy C.;Oliveira M.;Rovira P.S.;Seo J.H.;Valero V.;Vidal G.;Wong A.;Allison M.A.K.;Figlin R.;Chan D.;Chen S.-C.;Chen Y.-H.;Cobleigh M.;De Braud F.;Dirix L.;Hansen V.;Bessard A.H.;Iannotti N.;Isakoff S.;Lawler W.;Monta?O A.;Salkini M.;Seigel L.;On Behalf Of The, Lotus Investigators, Lotus Investigators; Estevez L.G.; De Laurentiis M.; Sohn J.H.; Wang H.-C.; Blau S.; Dent R.; Tan A.; Espi? M.; Im S.-A.; Lee K.S.; Kim S.-B.; Baselga J.; Kim S.-B.; Maslyar D.J.; Dent R.; Im S.-A.; Espi? M.; Blau S.; Tan A.R.; Isakoff S.J.; Oliveira M.; Saura C.; Wongchenko M.J.; Kapp A.V.; Chan W.Y.; Singel S.M.; Allison M.A.K.; Vidal G.; Wong A.; Valero V.; Seo J.H.; CHIUN-SHENG HUANG; Romieu G.; Velez M.; Villanueva R.; Conte P.F.; Dakhil S.; Debled M.; Martin A.G.; Hurvitz S.; Kim J.H.; Levy C.; Oliveira M.; Rovira P.S.; on behalf of the, LOTUS investigators, LOTUS investigators; Seigel L.; Salkini M.; Monta?o A.; Figlin R.; Chan D.; Chen S.-C.; Chen Y.-H.; Cobleigh M.; De Braud F.; Dirix L.; Hansen V.; Bessard A.H.; Iannotti N.; Isakoff S.; Lawler W. |
| 國立成功大學 |
2017 |
RNA sequencing to predict response to neoadjuvant anti-HER2 therapy a secondary analysis of the NeoALTTO randomized clinical trial
|
Fumagalli, D.;Venet, D.;Ignatiadis, M.;Azim, H.A.;Jr;Maetens, Maetens M.;Roth�, F.;Salgado, R.;Bradbury, I.;Pusztai, L.;Harbeck, N.;Gomez, H.;Chang, T.-W.;Coccia-Portugal, M.A.;Di, Cosimo S.;De, Azambuja E.;De, La Pe�a L.;Nuciforo, P.;Brase, J.C.;Huober, J.;Baselga, J.;Piccart, M.;Loi, S.;Sotiriou, C. |
| 臺大學術典藏 |
2016 |
Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial
|
Piccart-Gebhart M.; Holmes E.; Baselga J.; De Azambuja E.; Dueck A.C.; Viale G.; Zujewski J.A.; Goldhirsch A.; Armour A.; Pritchard K.I.; McCullough A.E.; Dolci S.; McFadden E.; Holmes A.P.; Tonghua L.; Im Y.-H.; CHIUN-SHENG HUANG; D?eras V.; Hillman D.W.; Wolff A.C.; Jackisch C.; Lang I.; Untch M.; Smith I.; Boyle F.; Xu B.; Gomez H.; Suter T.; Gelber R.D.; Perez E.A.; Eidtmann H.; Dinh P.; Di Cosimo S.; Harbeck N.; Tjulandin S. |
| 國立成功大學 |
2015-09 |
Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial
|
Sotiriou, C.; Venet, D.; Fumagalli, D.; Maetens, M.; Rothe, F.; Ignatiadis, M.; Bradbury, I.; Harbeck, N.; Gomez, H.; Chang, T. W.; Coccia-Portugal, M. A.; Di Cosimo, S.; De Azambuja, E.; De la Pena, L.; Nuciforo, P.; Armour, A.; Eidtmann, H.; Baselga, J.; Piccart, M.; Loi, S. |
Showing items 11-14 of 14 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
